Hims & Hers Health Inc (HIMS) stock plunged 5.56% in the pre-market trading session on Friday, following Citi's downgrade of the stock rating to "sell" from "neutral" and lowering of its GLP-1 revenue estimates for the company.
Citi analysts cited concerns that the market is overvaluing HIMS' GLP-1 revenue stream, as Novo Nordisk's semaglutide, the active ingredient in weight-loss drug Wegovy, could be removed from the FDA's shortage list in the next 12 months. This would significantly constrain HIMS' weight loss market, as they would only be able to compound GLP-1s by changing the formulation for specific clinical benefits.
HIMS currently sells compounded versions of semaglutide. Citi now expects HIMS' GLP-1 revenue to be $135 million in FY25, down from its previous estimate of $400 million. The brokerage's analysts believe that if semaglutide is removed from the shortage list, HIMS' weight loss market would be substantially limited.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。